Prognostic Value Of New IASLC/ATS/ERS Adenocarcinoma Sub-Classification Confirmed By Study
Researchers looked at patients with lung adenocarcinoma who underwent pulmonary resection between January 2001 and December 2009 at Kyoto University Hospital, Japan. The histological investigation included 440 lung adenocarcinomas, which met the 2004 WHO criteria for primary lung adenocarcinoma. Tumor staging was performed according to the 7th edition of the tumor, node, metastasis classification of the International Union Against Cancer.
Researchers concluded that the new classification identifies histologic subtypes of lung adenocarcinomas with prognostic value among Japanese patients. Moreover, they say, "EGFR mutations were significantly identified in AIS/MIA/Lepidic/Pap subtypes. Conversely, KRAS mutations were frequently identified in mucinous subtypes."
On the basis of these findings, they conclude, "that histologic subtyping and molecular testing for EGFR and KRAS mutations are helpful for predicting prognosis among patients with resectable lung cancer and may be helpful in selecting patients who require adjuvant chemotherapy."
The lead author of this work is Dr. Akihiko Yoshizawa. Co-authors include IASLC members Dr. Masashi Kobayashi, Dr. William Travis and Dr. Hiroshi Date.
International Association for the Study of Lung Cancer
Source: EurekAlert!, the online, global news service operated by AAAS, the science society
Please use one of the following formats to cite this article in your essay, paper or report:
International Association for the Study of Lung Ca. "Prognostic Value Of New IASLC/ATS/ERS Adenocarcinoma Sub-Classification Confirmed By Study." Medical News Today. MediLexicon, Intl., 20 Dec. 2012. Web.
25 Mar. 2017. <http://www.medicalnewstoday.com/releases/254132.php>
International Association for the Study of Lung Ca. (2012, December 20). "Prognostic Value Of New IASLC/ATS/ERS Adenocarcinoma Sub-Classification Confirmed By Study." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.